PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
-26.14%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
-26.43%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
-26.52%
Negative EPS growth underscores deteriorating earnings per share. Benjamin Graham would worry about ongoing dilution or weakened profitability.
-26.52%
Negative diluted EPS growth suggests diluted shares grew or net income fell. Benjamin Graham would see this as a serious setback to shareholder value.
0.09%
Share count up to +3% – Slight dilution. Howard Marks would be cautious but might accept it if used for profitable growth investments.
0.09%
Diluted share count up to +3% – Modest dilution. Howard Marks might tolerate it if used for high-ROI projects or strategic acquisitions.
No Data
No Data available this quarter, please select a different quarter.
-57.07%
Negative OCF growth is a critical warning sign. Benjamin Graham would check if receivables are ballooning or if core sales are declining.
-57.72%
Negative FCF growth reveals potential liquidity pressures or large capex overshadowing cash generation. Benjamin Graham would demand deeper scrutiny.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13659.85%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
12.78%
5Y OCF/share CAGR 10-15% – Strong. Benjamin Graham might investigate whether working-capital maneuvers artificially boosted OCF.
32.48%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
-18544.23%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
7.55%
5Y net income/share CAGR 7-10% – Decent. Seth Klarman would investigate cyclical recovery vs. stable expansions.
44.34%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
1862.49%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
309.42%
5Y equity/share CAGR above 12% – Strong mid-term book value expansion. Warren Buffett would see if steady profits and moderate payout ratios sustain this pace.
-81.93%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
Negative asset growth may reflect divestitures or depreciation outpacing new investments. Benjamin Graham wonders if shedding non-core assets improves focus or signals trouble.
-33.19%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D growth 20-30% – High. Howard Marks questions ROI unless the pipeline is robust or near commercialization.
24.63%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.